Our Technology
Conveyxo is unlocking regenerative medicine at scale to tackle the root causes of degenerative and inflammatory diseases that currently have no real cure.
Conveyxo tackle industrialization challenges from the start, making RNA-enhanced exosomes Triple-A : available, accessible and amplified.
To unlock RNA-enhanced exosomes potential, Conveyxo developed a technology platform based on:
- Single cell line sourcing
- Proprietary manufacturing technology
- Exclusive exosomes loading system
Current treatments for degenerative and inflammatory diseases only manage symptoms, not their root cause. Regenerative therapies are not yet approved given their challenges with predictability, scalability and affordability, leaving a massive unmet need.
Conveyxo is unlocking regenerative medicine at scale to tackle the root causes of degenerative and inflammatory diseases that currently have no real cure. Its unique “Triple-A” approach precisely addresses bottlenecks hampering development of these therapies.
Our exosomes come from one a single donor Wharton’s-jelly mesenchymal stem cell line, that we immortalized to guarantee consistent potency batch after batch.
With one donor, we can produce billion doses of treatment, while competing technologies would need 10²⁴ donors, creating high potency variability.
Our proprietary 3D printed fixed-bed bioreactors mimic the optimal cell growth conditions and enable industrial-scale production at a fraction of the costs. This overcomes the common scaling challenges in regenerative medicine.
Our patented microfluidic-based loading technology is based on a temporary mechanical porosity of the exosomes for payload absorption (mechanoporation). This process enables the loading of cargo, such as RNA, into exosomes without altering their natural therapeutic properties, boosting efficacy while preserving their integrity. Competing methods often compromise exosome quality or increase rejection risk.
